Mitchell Lawrence Jones's Insider Trades & SAST Disclosures
Mitchell Lawrence Jones's most recent trade in Palisade Bio Inc was a trade of 29,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 11, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mitchell Lawrence Jones.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Palisade Bio Inc | Mitchell Lawrence Jones | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 29,000 | 29,000 | - | - | Stock Option (Right to Buy) | |
| Palisade Bio Inc | Mitchell Lawrence Jones | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 24,000 | 24,000 | - | - | Restricted Stock Units | |
| Palisade Bio Inc | Mitchell Lawrence Jones | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 2,735 | 0 | - | - | Restricted Stock Units | |
| Palisade Bio Inc | Mitchell Lawrence Jones | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 2,735 | 3,568 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | Mitchell Lawrence Jones | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 1,555 | 4,313 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | Mitchell Lawrence Jones | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 1,555 | 0 | - | - | Restricted Stock Units | |
| Palisade Bio Inc | Mitchell Lawrence Jones | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 28 May 2024 | 810 | 2,758 | - | 4.8 | 3,856 | Common Stock, par value $0.01 |
| Palisade Bio Inc | Mitchell Lawrence Jones | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 28 May 2024 | 461 | 3,852 | - | 4.8 | 2,194 | Common Stock, par value $0.01 |
| Palisade Bio Inc | Mitchell Lawrence Jones | CEO, CFO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 304 | 2,735 | - | - | Restricted Stock Units | |
| Palisade Bio Inc | Mitchell Lawrence Jones | CEO, CFO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 304 | 814 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | Mitchell Lawrence Jones | CEO, CFO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 156 | 1,555 | - | - | Restricted Stock Units | |
| Palisade Bio Inc | Mitchell Lawrence Jones | CEO, CFO, Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 156 | 880 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | Mitchell Lawrence Jones | CEO, CFO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 06 May 2024 | 90 | 724 | - | 8.5 | 761 | Common Stock, par value $0.01 |
| Palisade Bio Inc | Mitchell Lawrence Jones | CEO, CFO, Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.47 per share. | 06 May 2024 | 47 | 833 | - | 8.5 | 398 | Common Stock, par value $0.01 |
| Palisade Bio Inc | Lawrence Mitchell Jones | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 4,558 | 45,586 | - | - | Restricted Stock Units | |
| Palisade Bio Inc | Jones Lawrence Mitchell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 4,558 | 7,482 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | Lawrence Mitchell Jones | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 2,333 | 25,667 | - | - | Restricted Stock Units | |
| Palisade Bio Inc | Lawrence Mitchell Jones | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2023 | 2,333 | 9,815 | - | 0 | Common Stock, par value $0.01 | |
| Palisade Bio Inc | Lawrence Jones Mitchell | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.44 per share. | 06 Feb 2023 | 2,153 | 7,662 | - | 0.4 | 939 | Common Stock, par value $0.01 |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges